Saeed Bahrampour

Saeed Bahrampour

Auto-generated profile, based on publicly available information

Saeed Bahrampour

Applied Cellular and Molecular Research Center Kerman University of Medical Sciences Kerman Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in International Journal of Endocrinology
Verified
Journal Article
Open access
MAMina Asadikaram
Mina Asadikaram
SBSaeed Bahrampour
Saeed Bahrampour
MNMahdis Rahimi Naiini
Mahdis Rahimi Naiini
AJAbdollah Jafarzadeh
Abdollah Jafarzadeh
CRClifford J Rosen
Clifford J Rosen
GAG.R. Asadi
G.R. Asadi
Prolactin (PRL) is secreted by various cells in the anterior pituitary gland, mammary glands, placenta, uterus, ovaries, testes, skin, adipose tissue, endothelial cells, immune system, and central nervous system. The expression and secretion of PRL are influenced by several factors such as suckling, thyrotropin‐releasing hormone (TRH), cytokines, dopamine, estrogen, and vasoactive intestinal polypeptide. It operates through a complex receptor, which is expressed in mammary gland cells, pancreatic beta cells, adipocytes, and immune cells. PRL is essential for various physiological functions, in particular milk production, breast development, metabolism, and immune regulation. Serum PRL levels fluctuate daily and can be affected by exercise, diet, and stress. Hyperprolactinemia is linked to autoimmune diseases and viral infections. In viral infections such as HIV, HCMV, HCV, and COVID‐19, PRL levels are often increased, which may influence the immune responses. PRL can modulate the activity of various immune cells, including T cells, B cells, natural killer cells, and macrophages, mounting an effective immune response against viral infections. Moreover, PRL influences the production of cytokines that mediate and regulate immunity and inflammation. PRL stimulates B cells to produce antivirus antibodies that are essential for neutralizing viruses and preventing their spread within the body. PRL levels, varying by sex and life stage, may affect immune responses and susceptibility to viral infections. Moreover, overexpression of PRL was indicated in various autoimmune diseases. Overall, PRL is a complex hormone with significant implications for endocrine function, immune regulation, and immune responses to viral infections, highlighting the need for further research into its diverse roles in health and disease. This review summarizes current knowledge of the immunomodulatory effects of PRL in human viral infections and possibly its contribution to the development of autoimmune diseases.

5 December 2021 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
ZJZahra Jalali
Zahra Jalali
SBSaeed Bahrampour
Saeed Bahrampour
PKParvin Khalili
Parvin Khalili
NJNazanin Jalali
Nazanin Jalali
ANAli Esmaeili Nadimi
Ali Esmaeili Nadimi
TSTabandeh Sadeghi
Tabandeh Sadeghi

22 February 2026 in Health Science Reports
Verified
Journal Article
Open access
PDF file
ZIZahra Isari
Zahra Isari
MGMelika Azizi Ghiasabadi
Melika Azizi Ghiasabadi
MGMohammad Amin Gharihe
Mohammad Amin Gharihe
AMAmir Mashayekhi
Amir Mashayekhi
AKAli Khashaveh
Ali Khashaveh
SNSeyed Aria Nejadghaderi
Seyed Aria Nejadghaderi
Background and Aims: As common disorders affecting the digestive system, gallbladder and biliary diseases present a significant health issue. This research aimed to assess the burden of these conditions in the Middle East and North Africa (MENA) region over the period of 1990 to 2021. Furthermore, we investigated the epidemiological characteristics of these diseases in relation to age, sex, and the Socio‐demographic Index (SDI). Methods: Drawing from the Global Burden of Disease (GBD) study 2021, we extracted data on the prevalence, incidence, and disability‐adjusted life years (DALYs) linked with gallbladder and biliary disease for 21 countries in the MENA region from 1990 to 2021. The results were presented as both absolute numbers and rates per 100,000 people, accompanied by their corresponding 95% uncertainty intervals (UIs). The association between disease burden and SDI was evaluated using smoothing spline models. Results: In 2021, the MENA region documented 4.8 million new cases of gallbladder and biliary diseases, with an age‐standardized incidence rate of 808.9 per 100,000 population, which represents a 5.0% reduction since 1990. The prevalence increased to 15.4 million cases, with an age‐standardized rate of 2807.5 per 100,000, marking a 7.9% decrease. The overall disease burden, quantified in DALYs, reached 437.1 thousand, with an age‐standardized rate of 85.7 per 100,000, signifying a 16.6% decline. Afghanistan estimated the highest DALY rates, while Oman had the lowest. A more pronounced burden was observed in females across all age brackets. An inverse correlation was identified between disease burden and SDI. Conclusion: Gallbladder and biliary diseases continue to be a public health challenge, particularly affecting women, the elderly, and nations with lower SDI levels. It is imperative for each country to develop healthcare systems and preventive measures that are tailored to its specific context.